Drug Profile
DNS 001
Alternative Names: DNS-001Latest Information Update: 10 Oct 2023
Price :
$50
*
At a glance
- Originator Dart NeuroScience
- Class Behavioural disorder therapies; Nootropics; Small molecules
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Memory disorders
Most Recent Events
- 10 Oct 2023 DNS 001 is still in phase I trials for Memory disorders in USA (Dart NeuroScience, October 2023)
- 28 Jan 2022 No recent reports of development identified for phase-I development in Memory disorders in USA
- 28 Jan 2020 DNS 001 is still in phase I trials for Memory disorders in USA (Dart NeuroScience, January 2020)